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In this study, a method was developed and validated for the quantification of metolazone
in human plasma samples. This method involves high-performance liquid chromatog-
raphy coupled with tandem mass spectrometry and is more sensitive, selective and rapid
than currently available methods. Chromatography was performed using a Phenomenex
Luna C18 column (100 mm  2.0 mm, 5 mm, 100 A˚) with an isocratic mobile phase of 0.1%
formic acid:acetonitrile (40:60, v/v) and zaleplon as an internal standard. The drug and
internal standard were extracted by liquideliquid extraction and analyzed by mass spec-
trometry in the multiple reaction monitoring mode by usingm/z values of 366.20/259.10 for
metolazone and 306.20/235.60 for zaleplon. The calibration curve was linear over metola-
zone concentrations ranging from 0.02 ng/mL to 15 ng/mL. The lower limit of quantification
was 0.02 ng/mL. Intra- and inter-assay precisions were 0.9e4.8% and 4.2e6.3%, respec-
tively. The intra- and inter-assay accuracies in quantifying metolazone were 97.5e102.3%
and 99.2e104.0%, respectively. Metolazone and zaleplon were eluted within 3.6 minutes,
and the retention time was 1.75 minutes for metolazone and zaleplon. The validated
method was successfully applied to a pharmacokinetic study of metolazone in human
plasma.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction delivery, which in turn is linked to its plasma content andMetolazone (2-methyl-3-o-tolyl-6-sulphamyl-7-chloro-1,2,3,4-
tetrahydro-4-quinazolinone) is a diuretic, saluretic and anti-
hypertensive drug of the quinazoline class with therapeutic
characteristics comparable to those of thiazide diuretics [1e3].
Metolazone inhibits sodium reabsorption primarily at the
cortical diluting site in the renal tubules. This occurs to a lesser
extent in the proximal convoluted tubule. The diuretic activity
of metolazone relates to the rate and extent of its urinary, Taipei Medical Univers
. Hsu).
ministration, Taiwan. Publindirectly to its concentrations in whole blood [4e8].
Metolazone is incompletely absorbed by the gastrointes-
tinal tract; the rate and extent of absorption depend on its
formulation. Approximately 95% of metolazone is in the
bound form in circulating blood, that is, 50e70% is bound to
red blood cells and 15e33% to plasma proteins. Its diuretic
effects persist for 24 hours [1e7].
The therapeutic doses of Mykrox (metolazone, 0.5 mg)
recommended for patients are low (0.5e1.0 mg) and result inity, 250 Wu-Hsing Street, Taipei 11031, Taiwan, ROC.
ished by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license.
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fore, a sensitive method is required. Several analytical
methods for the determination of metolazone concentrations
in biological fluids, including plasma, whole blood and urine,
are available. Existing analytical methods for detecting
metolazone include high-performance liquid chromatog-
raphy (HPLC) systems equipped with detectors using ultravi-
olet radiation, fluorescence andmass spectrometry [6,7,9e12].
HPLC methods have certain limitations and are not sensitive
enough for exact determination of terminal half-life in phar-
macokinetic studies involving lower doses (0.5 mg). Recently,
Jia et al. developed a liquid chromatography coupled with
tandem mass spectrometry (LCeMS/MS) method for the
quantitative determination of metolazone with a lower limit
of quantification (LLOQ) of 0.05 ng/mL. However, it is still
necessary to develop a more sensitive method to measure the
concentrations of metolazone in human plasma for advanced
pharmacokinetic profiles in low dose metolazone [10e12].
The purpose of the present study was to develop a simpler
and more rapid and sensitive assay for the quantitative
determination of metolazone in plasma samples. LCeMS/MS
systems are some of the most powerful analytical tools in
clinical pharmacokinetics owing to their selectivity, sensi-
tivity and reproducibility, and have been validated for line-
arity, precision and accuracy. The method described in the
present study was applied to a pharmacokinetic study. Phar-
macokinetic studies of metolazone have rarely been reported
and our present study provides pharmacokinetic data for
future reference.2. Methods
2.1. Chemicals
USP Reference Standard metolazone was purchased from the
United States Pharmacopeial Convention (Rockville, MD,
USA). Zaleplon (internal standard; 99.2%) was obtained from
Adamed Sp.zo.o (Warsaw, Poland). HPLC-grade acetonitrile
was purchased fromMallinckrodt Baker, Inc. (Phillipsburg, NJ,
USA). Analytical grade ammonium acetate, dipotassium
hydrogen phosphate, formic acid and acetic acid were pur-
chased from Merck KGaA (Darmstadt, Germany). Reagent-
grade diethyl ether was purchased from J.T. Baker (Phillips-
burg, NJ, USA). HPLC-gradewater was prepared using a Milli-Q
system (EMD Millipore Corp., Billerica, MA, USA).
2.2. Instrumentation
The HPLC system (1100 Series; Agilent Technologies, Wil-
mington, DE, USA) was equipped with an MS/MS detection
system consisting of an API 4000 model (Applied Biosystems,
Foster City, CA, USA). Data processing was performed with
Analyst 1.4 software (AB SCIEX, Framingham, MA, USA).
2.3. Chromatographic conditions
A Phenomenex Luna C18 column (100 mm  2.0 mm, 5 mm,
100 A˚) was selected as the analytical column. The mobile
phase was 0.1% formic acid:acetonitrile (40:60, v/v). The flowrate of themobile phase was 0.4mL/min, the injection volume
was 10 mL, and the column temperature was 35 C.
Electrospray ionization (ESI) was used in the positive ion
detectionmode. The capillary temperature wasmaintained at
500 C, the spray voltage was 4.5 kV, and the collision-
activated dissociation of the nitrogen gas was 5.0. The in-
strument was set up in multiple-reaction monitoring mode
and the transition m/z values were 366.20/259.10 for metola-
zone and 306.20/235.60 for zaleplon.
2.4. Preparation of calibration standards and quality
control samples
A stock solution of metolazone (100 mg/mL) was prepared by
dissolving metolazone in acetonitrile:water (50:50, v/v). Sub-
sequently, the working solution was serially diluted
(1e10,000 ng/mL) with acetonitrile:water (50:50, v/v). A cali-
bration curve was prepared using different concentrations of
working stock solutions. The calibration curves of metolazone
were prepared at the concentration levels of 0.02, 0.05, 0.1, 0.3,
1, 5, 10 and 15 ng/mL. The quality control (QC) samples were
prepared at concentrations of 0.02 ng/mL (LLOQ), 0.06 ng/mL
[low QC (LQC)], 0.6 ng/mL [medium QC (MQC)], and 12 ng/mL
[high QC (HQC)] with blank plasma, by separate weighing of a
reference standard. An internal standard of zaleplon (100 ng/
mL) was prepared by diluting a stock solution with acetoni-
trile:water (50:50, v/v). The calibration standards were pre-
pared fresh and the QC samples were stored in the freezer at
20 C until analysis. All the solutions were stored at 2e8 C
and brought to room temperature before use.
2.5. Sample preparation
Liquideliquid extraction was used to isolate metolazone and
zaleplon from human plasma. Briefly, 50 mL of zaleplon solu-
tion (100 ng/mL) was added to a 0.5-mL aliquot of plasma as
the internal standard for LCeMS/MS analysis. Following the
addition of 4 mL of diethyl ether, the samples were vortexed
for 5 minutes and then centrifuged at 1900g. The organic layer
was transferred to fresh tubes and evaporated to dryness
under a stream of nitrogen. Residues were reconstituted in
200 mL of mobile phase, and a 10-mL aliquot was injected into
the LCeMS/MS system.
2.6. Calibration curve, regression model, precision and
accuracy
The analytical curves were constructed using values ranging
from 0.02 ng/mL to 15 ng/mL in human plasma. Calibration
curves were obtained by weighted (1/concentration) least-
squares regression analysis. The ratio of the peak area of
metolazone to that of zaleplon was plotted against metola-
zone concentrations (ng/mL). Calibration curve standards and
QC samples were prepared for analysis in six replicates. Pre-
cision and accuracy for the interpolated concentrations of the
calibration points were maintained within 15% of their
nominal values. However, for the LLOQ, the precision and
accuracy were set within 20%. The matrix test was per-
formed to evaluate the suppression or enhancement of the
ionization of analytes and the internal standard by the
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present study, 12 blank plasma samples from six different
sources were prepared for the evaluation of matrix effect.
Following the sample preparation method, samples were
prepared to re-dissolve the solution step; 200 mL of 1.5 ng/mL
of metolazone and 25 ng/mL of the internal standard were
then added. After the analyses of all samples, the coefficients
of variance were calculated and used to evaluate the signifi-
cant influence of matrix effect.
2.7. LLOQ
The LLOQ was estimated in accordance with the baseline
noise method. It was estimated at a signal-to-noise ratio of
five. The LLOQ was experimentally determined by adminis-
tering six injections of metolazone at the LLOQ concentration.
The signal-to-noise ratio was calculated by selecting the noise
region as close as possible to the signal peak, which was at
least 10 times the width of the signal peak at half its height.
2.8. Recovery
The recovery of metolazone was evaluated by comparing the
mean peak area of six extracted LQC, MQC and HQC samples
and plasma samples with 0.06, 0.6 and 12 ng/mL metolazone
concentrations with the mean peak area of six unprocessed
samples (blank sample extracts spiked with working
solution).
2.9. Stability (freezeethaw, auto-sampler, long-term,
short-term)
LQC and HQC samples (n ¼ 3) were retrieved in triplicate from
the freezer after four freezeethaw cycles and were then
frozen at 20 C. The samples were thawed on the laboratory
bench or in a water bath at room temperature (25 C). Auto-
sampler stability was studied following a 24-hour storage
period in the auto-sampler tray. Long-term stability of meto-
lazone in the QC samples was also determined after 114 days
of storage at 20 C. Short-term stability was determined for
24 hours with LQC and HQC samples. Stability samples were
processed and extracted along with freshly spiked calibration
curve standards.
2.10. Application of the method
The methods described above were applied in a pharmacoki-
netic study involving 20 healthy male Taiwanese volunteers
(age range, 20e40 years). Theywere free from cardiac, hepatic,
renal, pulmonary, neurological, gastrointestinal and hema-
tological diseases, as assessed by physical examination,
electrocardiography analysis and laboratory analyses,
including hematology, biochemistry and electrolyte studies
and urinalysis. All subjects were instructed to abstain from
taking any medication for 2 weeks prior to and during the
entire study. The study protocol was approved by the Insti-
tutional Review Board of Mackay Memorial Hospital in
accordance with the principles of the Declaration of Helsinki.
Written informed consents were obtained from all the sub-
jects. The study was conducted according to a single-centeropen-label design. The study subjects fasted overnight and
were then administered a single oral dose of 0.5 mg metola-
zone tablets with 240 mL of water. Mykrox tablets were used
as an investigation drug. Standardized meals were served 4
and 10 hours after dosing. Venous blood samples (10mL) were
drawn in heparinized tubes before dosing (0 hours) and at 0.5,
1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 10, 12, 24, 36 and 48 hours
after drug administration. Plasma samples were immediately
separated by centrifugation at 1900g. All samples were stored
at 20 C until analysis.
2.11. Pharmacokinetic analysis
A non-compartmental pharmacokinetic method was used to
determine the pharmacokinetic parameters. Cmax, the
maximumobserved concentration, and Tmax, the time to peak
concentration, were determined for each subject and treat-
ment. The area under the concentrationetime curve from
time 0 to the last quantifiable concentration (AUC0et) was
determined by the trapezoidal rule. The area under the con-
centrationetime curve from time 0 to infinity (AUC0eN) was
determined by the trapezoidal rule and extrapolated to in-
finity, as estimated by the last quantifiable concentration
divided by the elimination rate constant (kel). The kel was
determined by simple linear regression based on the terminal
phase of plasma concentration. Plasma half-life (T1/2) was
estimated using the following calculation: 0.693/kel.3. Results and discussion
3.1. Chromatography
Chromatographic conditions were optimized in several trials
to achieve good resolution and symmetrical peak shapes. The
chromatograms of extracted human plasma samples are
shown in Fig. 1. No significant interfering peaks from endog-
enous components were observed in blank plasma (Fig. 1A).
The chromatographic retention time was 1.75 minutes for
metolazone and zaleplon with a total run time of 3.6 minutes.
Ourmetolazone retention time ismuch shorter than the times
of 6.3 minutes [10] and 3.7 minutes [12] reported previously.
The results suggest that the LCeMS/MS assay system is fast
and suitable for the analysis of metolazone in plasma
samples.
3.2. Linearity, precision, and accuracy
Thecalibration curve for the ratioof peakareaeconcentrationof
zaleplon versus that ofmetolazone showeda linear relationship
over a concentration range of 0.02 ng/mL to 15 ng/mL. The
regression equation of metolazone was y ¼ 0.6888x þ 0.000414,
and the correlation coefficient (r2) was 0.9998, indicating good
linearity. Deviation from the expected concentration ranged
from 97.4% to 102.0%, and the coefficients of variation were all
within 4% (Table 1).
Roy et al. also developed an LCeMS/MSmethod using ESIþ
tandem mass spectrometry for quantifying metolazone in
human plasma [11]. Jia et al. reported the determination of
metolazone in human plasma by liquid chromatography with
Fig. 1 e Chromatograms of (A) drug-free plasma sample and (B) plasma sample spiked with 0.02 ng/mL metolazone (lower
limit of quantification) and 10 ng/mL of zaleplon (internal standard).
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mL and 0.05 ng/mL reported in these two studies, which are
much higher than those obtained in the present study, indi-
cate that the sensitivity of the present method is sufficient for
bioanalysis.
Precision and accuracy were determined at four different
concentrations on six independent occasions. Table 2 shows
that the intra-assay coefficients of variation ranged from 0.9%
to 4.8%, and trueness ranged from 97.5% to 102.3%. The inter-
assay coefficients of variation ranged from 4.2% to 6.3%, and
trueness ranged from 99.2% to 104.0%, indicating that theTable 1 e Precision and accuracy of assays for plasma
spiked with metolazone.
Spiked concentration
(ng/mL)
Back-calculated
concentration (ng/mL)
0.02 0.0203  0.0008 (3.9)
0.05 0.0491  0.0013 (2.6)
0.1 0.100  0.002 (2.0)
0.3 0.306  0.006 (2.0)
1 1.01  0.2 (2.0)
5 4.82  0.03 (0.6)
10 10.1  0.2 (2.0)
15 15.0  0.2 (1.3)
Data are expressed as mean  standard deviation (coefficient of
variation %), n ¼ 5.assay method was sufficiently reliable and reproducible
within the required analytical range. Based on the results of
the matrix effect test, the coefficient of variation of 12 plasma
samples from six different sources was 1.3%. The results
indicated that the matrix component in human plasma did
not significantly affect response.3.3. Recovery
The recoveries of metolazone when added to plasma at con-
centrations of 0.06, 0.60 and 12.0 ng/mLwere 95.2%, 88.6% and
87.2%, respectively. The average recoveries of metolazone and
zaleplon, that is, 90.3% and 90.4%, respectively, were judged toTable 2 e Precision and accuracy of assays for detecting
metolazone in human plasma.
Intra-assay (n ¼ 5) Inter-assay (n ¼ 30)
Metolazone
(ng/mL)
0.02 0.06 0.6 12 0.02 0.06 0.6 12
Mean
metolazone
(ng/mL)
0.0203 0.0608 0.614 11.7 0.0208 0.0622 0.609 11.9
CV (%) 3.4 4.8 3.9 0.9 4.8 6.3 4.4 4.2
RE (%) 1.5 1.3 2.3 2.5 4.0 3.7 1.5 0.8
Trueness (%) 101.5 101.3 102.3 97.5 104.0 103.7 101.5 99.2
CV ¼ coefficient of variation; RE ¼ relative error.
Table 3 e Stability of metolazone in three human plasma
samples.
Stability (mean of percentage
remaining, %)
Metolazone
concentration
(ng/mL)
0.06 12
Short-term (24 h, room temperature) 92.5% 94.2%
Auto-sampler (24 h, room temperature) 111.5% 104.2%
Freezeethaw in air (laboratory bench)
(4 cycles)
103.0% 95.0%
Freezeethaw in water bath (4 cycles) 99.8% 95.8%
Long-term storage at 20 C (114 d) 101.5% 98.3%
Table 4 e Pharmacokinetic parameters of metolazone
following a single oral dose administered to healthy
subjects in the present study and in Jia et al.’s study [12].
Present study
(n ¼ 20)
Jia et al.’s study (n ¼ 10)
0.5 mg 0.5 mg 1 mg 2 mg
AUC0et
(h  ng/mL)
56.5  10.4 33.9  9.2 122.5  36.3 162.4  26.9
AUC0eN
(h  ng/mL)
57.3  10.8 34.2  8.9 123.9  37.0 164.1  27.5
Cmax (ng/mL) 8.71  1.16 6.9  2.6 20.6  4.8 36.8  7.1
MRT (h) 9.07  1.34 5.7  1.0 8.1  1.3 6.8  1.5
Tmax (h) 1.78  0.77 1.55  0.9 1.60  0.6 1.45  1.3
T1/2 (h) 8.27  0.86 6.6  2.8 7.9  1.2 6.8  1.5
Data are expressed as mean  standard deviation.
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method exceeded the 69.8e74.7% [10] and 70.5e72.6% [12] re-
ported previously, whichmay be due to the lower LLOQ of this
bioanalytical method.
3.4. Stability studies
Table 3 summarizes the results of the stability studies and
shows that the analytes were stable after plasma samples
were subjected to four freezeethaw cycles (20 C to 25 C).
Differences in metolazone concentrations after the fourth
freezeethaw cycle ranged from 95.0% to 103.0%. The results
indicated that metolazone was stable in human plasma after
four freezeethaw cycles. No significant degradation was
observed even after a 24-hour storage period in the auto-
sampler tray, and the final concentrations of metolazone
ranged from 104.2% to 111.5%. Moreover, the long-term sta-
bility of metolazone in the LQC and HQC samples after 114
days of storage at 20 C was also evaluated, and metolazone
concentrations ranged from 98.3% to 101.5%.
3.5. Application to a pharmacokinetic study
We next determined the pharmacokinetics of a single 0.5-mg
dose (1 tablet) of metolazone in 20 healthy male volunteers.
Fig. 2 shows a representative plot of plasma concentration as a
function of time. Published LLOQs are not low enough to allow
the determination of metolazone concentrations in human
plasma following a 0.5mg dose [10e12]. The LLOQ determined
here was 0.02 ng/mL. Our present results showed that theTime (h)
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Fig. 2 e Mean plasma concentrationetime profile after oral
administration of 0.5 mg metolazone tablets.presented timeeconcentration profiles were clearer than
those in human whole blood [10].
The pharmacokinetic characteristics are consistent with
those of other studies administering 1e2 mg of metolazone in
human plasma [10e12]. Compared to the published data on
administering 0.5 mg of metolazone, the variations in phar-
macokinetic parameters are higher, and the AUC values are
smaller than those reported in the current study [12]. We
conjecture that the difference might be due to the sensitivity
of this bioanalytical method.
The plasma concentrations of metolazone were within the
calibration curve range and remained above the 0.02 ng/mL
sensitivity limit for the entire sampling period. AUC0et and
AUC0eN were 56.5  10.4 h  ng/mL and 57.3  10.8 h  ng/mL,
respectively. Cmaxwas8.71 1.16ng/mLandT1/2was8.27 0.86
hours. Themean ratio of AUC0et/AUC0eN was over 90%. All the
pharmacokineticparametersofmetolazoneare listed inTable4.
In the present study, we could determine the concentra-
tions of metolazone up to 48 hours after the oral administra-
tion of 0.5mg to healthy volunteers. Thus, we could assess the
drug’s elimination phase by using a more efficient extraction
method coupled with more sensitive analytical techniques.
The methods developed in the present study are suitable for
pharmacokinetic studies.4. Conclusion
A simple, rapid and specific liquid chromatography tandem
mass spectrometric method was developed and validated for
the quantitative measurement of metolazone. It could be
prepared by liquideliquid extraction, separated by a Luna C18
column and quantified by LCeMS/MS. This method offers the
advantages of higher sensitivity and shorter run time. It was
successfully applied to characterize the pharmacokinetics of
metolazone in healthy volunteers.r e f e r e n c e s
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